Lv11
10 积分 2022-12-08 加入
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2小时前
已完结
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
4小时前
已完结
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
1个月前
已完结
Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies?
2个月前
已完结
Preclinical Assessment of the PI3Kα Selective Inhibitor Inavolisib and Prediction of Its Pharmacokinetics and Efficacious Dose in Human
2个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
2个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
2个月前
已完结
A single inhibitor for all KRAS mutations
3个月前
已完结
Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers
3个月前
已完结
Targeting KRAS in cancer
3个月前
已完结
皖公网安备34019202002308
